Loading
NASDAQHealthcareBiotechnology
Latest quote
$72.53
+$0.10 · +0.14%
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Previous close
$72.53
+$0.10 · +0.14%
After-hours
$72.54
+$0.01 · +0.01%
Oct 7, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Day range
Current $72.53
52-week range
Current $72.53
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
48
Fair Value
Sentiment
58
Mixed
Risk
41
Elevated Risk
Momentum
62
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Day range
Current $72.53
52-week range
Current $72.53
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | 1.22B USD | 1.22B USD | 1.16B USD | 1.14B USD | 1.11B USD |
| Cost of goods sold | 415.97M USD | 429.36M USD | 389.34M USD | 366.89M USD | 349.1M USD |
| Gross profit | 799.07M USD | 790.27M USD | 769.73M USD | 769.82M USD | 756.5M USD |
| Research and development | 94.77M USD | 99.5M USD | 96.66M USD | 92.49M USD | 87.14M USD |
| Selling, general, and administrative | 452.42M USD | 415.1M USD | 393.32M USD | 352.44M USD | 339M USD |
| Operating expenses | 547.18M USD | 688.02M USD | 563.04M USD | 470.87M USD | 459.91M USD |
| Interest income | — | 3.89M USD | 3.32M USD | 3.41M USD | 794K USD |
| Interest expense | 5.41M USD | 8.51M USD | 15.74M USD | 11.22M USD | 11.31M USD |
| Depreciation and amortization | 97.36M USD | 109.9M USD | 111.71M USD | 107.24M USD | 101.07M USD |
| Operating income | 251.89M USD | 102.26M USD | 206.69M USD | 298.94M USD | 296.59M USD |
| Net income | 181.86M USD | 73.4M USD | 168.11M USD | 285.26M USD | 272.05M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$65.78
9.31% downside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Nov 30, 2022 | 4:1 | — | — |
Stock split | Dec 4, 2000 | 2:1 | — | — |
Stock split | Nov 18, 1997 | 2:1 | — | — |
Effective Nov 30, 2022
4:1
Effective Dec 4, 2000
2:1
Effective Nov 18, 1997
2:1
Funds reporting this stock among their holdings, ordered by reported position size.
State Street SPDR S&P 500 ETF1557.T21.9B0.02%129.41T JPY0.09%¥122,700-0.57%
Vanguard Morningstar Total Stock Market ETFVTI360.03M0.02%2.3T USD0.03%$381.03-0.40%
Vanguard S&P 500 ETFVOO300.79M0.02%1.8T USD0.03%$714.34-0.26%
Vanguard Morningstar Small-Cap ETFVB260.48M0.14%185.3B USD0.03%$286.98-1.41%
Invesco S&P 500 Equal Weight ETFRSP194.87M0.20%96.47B USD0.20%$210.6-0.81%
iShares Core S&P 500 ETFIVV151.32M0.02%899.63B USD0.03%$780.58-0.25%
Vanguard Morningstar Small-Cap Growth ETFVBK149.52M0.33%44.7B USD0.05%$342.24-1.50%
State Street SPDR S&P 500 ETFSPY138.29M0.02%819.04B USD0.09%$777.22-0.24%State Street SPDR S&P 500 ETF1557.TVanguard Morningstar Total Stock Market ETFVTIVanguard S&P 500 ETFVOOVanguard Morningstar Small-Cap ETFVBInvesco S&P 500 Equal Weight ETFRSPiShares Core S&P 500 ETFIVVVanguard Morningstar Small-Cap Growth ETFVBKState Street SPDR S&P 500 ETFSPYAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
